Explore how blood-based biomarkers are changing Alzheimer’s disease diagnosis through early detection and less invasive testing. Discover emerging biomarkers, FDA-approved tests, advanced diagnostic technologies, and clinical trial developments.
Alzheimer’s disease (AD) is the most prevalent neurological disorder characterized by memory loss, cognitive decline, and behavioral changes. It accounts for approximately 60% of 57 million dementia cases globally, with prevalence projected to exceed 100 million by 2050. Blood-based biomarkers are an emerging approach for the prevention and early diagnosis of AD.
Blood-Based Biomarkers: Recognizing Early-Onset AD
Early diagnosis and prevention of AD are essential, as they enable healthcare professionals to change how the condition can be managed and slow down its progression. Conventional diagnostic approaches are based on cerebrospinal fluid (CSF) biomarker analysis and neuroimaging modalities like magnetic resonance imaging (MRI) and positron emission tomography (PET). CSF biomarker analysis identifies and quantifies certain biomarkers involved in AD progression, while neuroimaging modalities measure structural brain alterations. These techniques face limitations due to invasiveness, high costs, and limited accessibility.
To overcome several limitations of conventional diagnostic techniques for AD, researchers focus on the development of novel approaches to measure blood-based biomarkers. Blood tests offer a minimally invasive diagnostic approach and are significantly cost-effective. These tests detect AD biomarkers, such as phosphorylated tau proteins (p-tau217, p-tau181), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and amyloid-β40/42. They offer high sensitivity, strong specificity, and clinical applicability to enable timely intervention and improve patient outcomes.
FDA-Approved Blood-Based Biomarkers Detection Tools
The U.S. Food and Drug Administration has approved a total of 4 detection tools that can detect AD biomarkers using blood tests among patients experiencing clinical symptoms of cognitive decline. This marks a major milestone in the diagnostic sector, encouraging researchers to explore more blood-based diagnostic approaches for AD.
Advanced Blood-Based Biomarker Detection Technologies
Blood-based biomarkers are detected through blood tests using a syringe. The blood collected is then evaluated using several analytical techniques. These techniques include ultrasensitive immunoassay, mass spectrometry, proteomics & multi-omics, and dried blood spot testing. Single-molecule array (Simoa) technology, a type of ultrasensitive immunoassay, is widely used due to its unparalleled sensitivity and uses digital ELISA principles for reliable quantification of low-abundance biomarkers. Microfluidic-based platforms, like the Ella system, offer automated, reproducible detection with less inter-operator variability.
Mass spectrometry is another essential tool for detecting blood-based biomarkers using antibody-based assays. It offers superior sensitivity and specificity and enables the quantification of ultra-low levels of biomarkers. Proteomics is a novel approach that enables simultaneous quantitative detection of hundreds to over 11,000 proteins. Additionally, since AD primarily affects the geriatric population, the need for at-home testing rises significantly. Dried blood spot testing enables at-home or point-of-care testing.
Clinical Trial Landscape of Blood-Based Biomarkers
Blood-based biomarkers hold great promise to revolutionize the diagnosis and prognostic work-up of AD in clinical practice. As of 18th November 2026, 52 clinical trial studies were registered related to blood-based biomarkers for AD on the clinicaltrials.gov website. This indicates the progress of the development of blood-based biomarkers. The urge to simplify and improve clinical practice related to AD has encouraged researchers to study blood-based biomarker detection among patients.
According to a review report by the Alzheimer’s Association, as of 1st January 2025, 13 disease-targeted therapeutic (DTT) trials (10%) accepted a blood-based biomarker as eligibility criteria for the trial. Of these, 3 were in Phase 3, 8 in Phase 2, and 2 in Phase 1. In addition, blood-based biomarkers were included as primary outcome measures in 13 trials, while as secondary outcome measures in 18 trials. It has been found that blood-based biomarkers facilitate trial participant screening, help broaden participation, and enhance trial population diversity.
For instance,
- Researchers from Alamar Biosciences have developed a new blood test that shows the extent to which AD has progressed in the brain. The test measures levels of a biomarker, eMTBR-tau, which indicates the accumulation of tau proteins in the brain cells. (https://www.reuters.com/business/healthcare-pharmaceuticals/new-blood-test-measures-alzheimers-progression-2026-11-18/)
Conclusion
Blood-based biomarkers are transforming the landscape of AD diagnosis by offering a minimally invasive, cost-effective, and accessible approach to early disease detection. The emergence of biomarkers, such as p-tau217, p-tau181, NfL, GFAP, and Aβ, alongside FDA-approved diagnostic tools, highlights the significant progress in routine AD testing.
Furthermore, advancements in technologies, such as SIMOA, mass spectroscopy, proteomics, and dried blood spot testing, are expanding the possibilities of more efficient detection.
With growing clinical trial activity and increasing pharmaceutical industry interest, blood-based biomarkers are expected to play an increasingly important role in AD research and clinical practice. These innovations could transform early diagnosis, improve patient screening, and support timely intervention. Blood-based biomarkers summarize AD pathological features identified by CSF analysis and neuroimaging, demonstrating the potential to partially or fully replace traditional diagnostic modalities. Thus, blood-based testing represents a promising step toward making AD detection more accessible, efficient, and patient-friendly.
About the Authors
Aditi Shivarkar
Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.
Aman Singh
Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.
Piyush Pawar
Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.
Request Consultation